Pharma boss: Some EU countries effectively delay market entry of generics

By |marec 17th, 2017|Biosimilar medicines, clinical tests, drug pricing, generic drugs, medicines, News|

The harmonisation of different regulatory environments in the EU member states will help generic drugs enter the market, resulting in reduced prices for medicine and better patient access, Jacek Glinka told EURACTIV.com in an interview.